NTLA : SWING TRADE
Güncellendi
Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Summary :
Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology.
Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 96%.
This was the first ever clinical proof of the safety and efficacy of an in-vivo CRISPR genome editing technology in a human trial, and sent Intellia's share price up by >100%.
Intellia will release more data from the trial and initiate a single-dose expansion cohort before the end of the year.
SOURCE : Edmund Ingham, Aug. 31, 2021, Seeking Alpha
seekingalpha.com/article/4452837-intellias-data-has-underlined-huge-potential-of-gene-therapeutics
Summary :
Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology.
Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 96%.
This was the first ever clinical proof of the safety and efficacy of an in-vivo CRISPR genome editing technology in a human trial, and sent Intellia's share price up by >100%.
Intellia will release more data from the trial and initiate a single-dose expansion cohort before the end of the year.
SOURCE : Edmund Ingham, Aug. 31, 2021, Seeking Alpha
seekingalpha.com/article/4452837-intellias-data-has-underlined-huge-potential-of-gene-therapeutics
Emir iptal
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.